---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-116233"
form_type: "8-K"
ticker: "MBIO"
cik: "0001680048"
company_name: "MUSTANG BIO, INC."
filed_at: "2026-10-15T20:05:21+00:00"
generated_at: "2026-10-15T20:06:05.881139+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mustang Bio wins second Nasdaq grace period to April 12, 2027; reverse stock split possible

## Summary
- Nasdaq staff granted MBIO an additional 180-calendar-day period, until April 12, 2027, to regain the $1.00 minimum bid price requirement.
- Company failed to regain compliance by the initial deadline of October 12, 2026, set after the April 15, 2026 deficiency notice.
- Original notice: common stock closed below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Compliance requires a closing bid of at least $1.00 for 10 consecutive business days (generally not more than 20).
- Mustang Bio told Nasdaq it may effect a reverse stock split if necessary; if it fails, staff would notify of delisting, appealable to the Nasdaq Hearings Panel without pausing any trading suspension.

## SEC filing metadata
- accession: 0001104659-26-116233
- form_type: 8-K
- ticker: MBIO
- cik: 0001680048
- company_name: MUSTANG BIO, INC.
- filed_at: 2026-10-15T20:05:21+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680048/000110465926116233/0001104659-26-116233-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680048/000110465926116233/tmb-20261013x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-116233
- JSON: https://secwatch.observer/filing/0001104659-26-116233.json
- Plain text: https://secwatch.observer/filing/0001104659-26-116233.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.